Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?

ABSTRACT: The advent of anti-TNF agents as the first approved targeted therapy in the treatment of inflammatory bowel disease (IBD) patients has made a major impact on our existing therapeutic algorithms. They have not only been approved for induction and maintenance treatment in IBD patients, but have also enabled us to define and achieve novel therapeutic outcomes, such as combination of clinical symptom control and endoscopic remission, as well as mucosal healing. Nevertheless, approximately one third of treated patients do not respond to initiated anti-TNF therapy and these treatments are associated with sometimes severe systemic side-effects. There is therefore the currently unmet clinical need do establish predictive markers of response to identify the subgroup of IBD patients, that have a hei

SUBMITTER: Atreya R 

PROVIDER: S-EPMC7492550 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature